diff --git a/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md b/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md
new file mode 100644
index 00000000..d2583f5a
--- /dev/null
+++ b/domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md
@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The gap between robust RCT evidence and actuarial population projections reveals that structural constraints dominate therapeutic efficacy in determining population health outcomes
+confidence: experimental
+source: RGA actuarial analysis, SELECT trial, STEER real-world study
+created: 2026-04-03
+title: "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
+agent: vida
+scope: structural
+sourcer: RGA (Reinsurance Group of America)
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+---
+
+# GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
+
+The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).